Latest Conference Articles

Ixazomib, Cyclophosphamide Combo Effective for Newly Diagnosed Myeloma

An all-oral triplet therapy of ixazomib, cyclophosphamide, and dexamethasone demonstrated promising early response rates in elderly patients with newly diagnosed multiple myeloma.

Durable Daratumumab Activity Highlighted in Combined Myeloma Analysis

Treatment with the CD38 monoclonal antibody daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma.

Dr. Young on Eltrombopag Added to Immunosuppression for Patients With Aplastic Anemia

Neal Young, MD, senior investigator, Cell Biology Section, National Heart, Lung, and Blood Institute, National Institute of Health, discusses a study that examined the efficacy of eltrombopag when added to standard immunosuppression for patients with aplastic anemia.

Benefits of Elotuzumab Sustained in 3-Year Myeloma Data

The combination of elotuzumab, lenalidomide, and dexamethasone showed sustained improvements in progression-free survival and overall survival for patients with relapsed/refractory multiple myeloma.

Bortezomib Triplet Therapy New Standard of Care for Untreated Multiple Myeloma

Induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone significantly improved progression-free survival and overall survival compared with lenalidomide and dexamethasone alone for patients with untreated multiple myeloma.

Carfilzomib Bests Bortezomib Across Multiple Myeloma Subgroups

Treatment with carfilzomib reduced the risk of progression or death by 47% compared with bortezomib for patients with relapsed multiple myeloma.

Dr. Wierda on Combination Regimens With Venetoclax in CLL

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

Dr. Usmani on Ibrutinib/Carfilzomib in Patients With Multiple Myeloma

Saad Z. Usmani, MD, hematology and medical oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses results of a phase Ib/II study examining the combination of ibrutinib plus carfilzomib in patients with relapsed/refractory multiple myeloma.

Dr. van den Brink Highlights Four Abstracts From ASH 2015

Marcel R.M. van den Brink, MD, PhD, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

ASH 2015 Preview: Novel Agents, Combinations Abound Across Hematologic Malignancies

In less than 5 years, the treatment landscape for patients with hematologic malignancies has undergone a dramatic transformation, with continued advancements and pivotal data being presented at the 2015 ASH Annual Meeting.

Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma

Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.

Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

Michael Lim, MD, Director of Brain Tumor Immunotherapy, Associate Professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Dr. Gilbert on Precision Medicine in Glioblastoma

Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Vemurafenib/Cobimetinib Shows 30% OS Benefit in BRAF-Mutant Melanoma

Treatment with the combination of vemurafenib and cobimetinib improved overall survival by 4.9 months compared with vemurafenib alone for patients with BRAF mutation-positive advanced melanoma.

Pembrolizumab/Ipilimumab Combo Effective in Advanced Melanoma

A treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.

Optimizing Precision Medicine Approaches in Glioblastoma

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

'Groundbreaking' Global Brain Cancer Trial Planned

An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

Dr. Butowski on Real-Time Imaging of Nanoliposomal Irinotecan Injection

Nicholas A. Butowski, MD, discusses an early-stage study of convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.

Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBM

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

Factors Affecting Dabrafenib/Trametinib Outcomes in Melanoma Identified

In the largest-to-date analysis of treatment-naïve metastatic melanoma patients with BRAF V600 mutations treated with dabrafenib and trametinib, researchers have found that baseline LDH levels and number of disease sites were the most significant factors affecting survival.

Novel Pembrolizumab Combos Show Promising Responses in Melanoma

Two separate early phase clinical trials exploring pembrolizumab-containing immunotherapy combinations have shown objective response rates over 50% in patients with advanced melanoma.

Dr. Mrugala on Extending Treatment With Temozolomide in Glioblastoma

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

Rindopepimut Combo Continues to Show Strong OS Benefit in Relapsed GBM

Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.

Dr. Heimberger on FGL2 as a Regulator of Tumor-Mediated Immune Suppression

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

Understanding BRAF Resistance Critical to Advancing Melanoma Care

Making real strides in melanoma care requires an understanding of BRAF resistance mechanisms.

Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated Melanoma

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.

June Provides Insight Into Managing AEs From CAR T-Cell Therapies

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination

Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation, Queensland, discusses long-term data from the phase III CheckMate-066 trial.